Fudan University;The Ohio State University Research Foundation;The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services
发明人:
Ji, Junfang,Croce, Carlo M.,Tang, Zhao-You,Wang, Xin W.,Sun, Hui-Chuan
申请号：
AU2009257410
公开号：
AU2009257410B2
申请日:
2009.06.11
申请国别(地区):
AU
年份:
2014
代理人:
摘要：
It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN) - α therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-α therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents
